Bristol-Myers Squibb (BMY) stock shows potential for growth with recent FDA approval and strong oncology portfolio, but faces ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...

Shares of Bristol Myers Squibb Co. BMY inched 0.67% higher to $53.96 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

We estimate Bristol Myers Squibb’s Valuation to be $60 per share, reflecting around 20% upside from here. While BMY stock looks like it has ample room for growth, it is helpful to see how ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...